Amgen and UCB's Osteoporosis Drug Bests Lilly's Forteo in Study

  • Drugmakers test romosozumab on more than 200 women in trial
  • UCB stock shows biggest gain in more than five years

Amgen Inc. and Belgian partner UCB SA said an experimental osteoporosis drug designed to promote new bone growth helped mend older women’s hip bone density in an advanced clinical test, sending UCB’s stock to the highest level in more than five years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.